Advances in the identification of β-secretase inhibitors

Bibliography

• Available from: http://www.who.int/mental_health/publications/dementia_report_2012/en/index.html
   Google Scholar
• Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimer's Dementia 2012;8:131-68
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 2000;924:17-25
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. The deposition of amyloid proteins in the aging mammalian brain: implications for Alzheimer's disease. Ann Med 1989;21:73-6
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;399:A23-31
   PubMed Web of Science ®Google Scholar
• Sinha S, Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 1999;96:11049-53
   PubMed Web of Science ®Google Scholar
• Vassar R, Bennett BD, Babu-Khan S, et al. Beta-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-41
   PubMed Web of Science ®Google Scholar
• Hussain I, Powell D, Howlett DR, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Neuroscience 1999;14(6):419-27
   Web of Science ®Google Scholar
• Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999;402:533-7
   PubMed Web of Science ®Google Scholar
• Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999;402:537-40
   PubMed Web of Science ®Google Scholar
• Hamada Y, Kiso Y. Recent progress in the drug discovery of non-peptidic BACE1 inhibitors. Expert Opin Drug Discov 2009;4(4):391-416
   PubMed Web of Science ®Google Scholar
• Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragment in regulating neural activity, plasticity and memory. Prog Neurobiol 2003;70:1-32
   PubMed Web of Science ®Google Scholar
• Tabaton M, Tamagno E. The molecular link between beta- and gamma-secretase activity on the amyloid beta precursor protein. Cell Mol Life Sci 2007;64:2211-18
   PubMed Web of Science ®Google Scholar
• Fluhrer R, Capell A, Westmeyer G, et al. A non-amyloidogenic function of BACE-2 in the secretory pathway. J Neurochem 2002;81(5):1011-20
   PubMed Web of Science ®Google Scholar
• Citron M, Westaway D, Xia1 W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid -protein in both transfected cells and transgenic mice. Nat Med 1997;3:67-72
   PubMed Web of Science ®Google Scholar
• Citron M, Oltersdorf T, Haass C, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992;360(6405):672-4
   PubMed Web of Science ®Google Scholar
• Citron M, Teplow DB, Selkoe DJ. Generation of amyloid beta protein from its precursor is sequence specific. Neuron 1995;14(3):661-70
   PubMed Web of Science ®Google Scholar
• Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488(7409):96-9
   PubMed Web of Science ®Google Scholar
• Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001;10(12):1317-24
   PubMed Web of Science ®Google Scholar
• Cai J, Qi X, Kociok N, et al. Beta-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med 2012;4(9):980-91
   PubMed Web of Science ®Google Scholar
• Rajapaksha TW, Eimer WA, Bozza TC, et al. The Alzheimer's beta-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol Neurodegener 2011;6:88- doi: 10.1186/1750-1326-6-88
   PubMed Web of Science ®Google Scholar
• Cao L, Rickenbacher GT, Rodriguez S, et al. The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci Rep 2012;2:231- doi: 10.1038/srep00231
   PubMed Web of Science ®Google Scholar
• Hamada Y, Kiso Y. The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors. Expert Opin Drug Discov 2012;7(10):903-22
   PubMed Web of Science ®Google Scholar
• Mancini F, De Simone A, Andrisano V. Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors. Anal Bioanal Chem 2011;(7):1979-96
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Shin D, Downs D, et al. Design of potent inhibitors for human brain memapsin 2 (beta-secretase). J Am Chem Soc 2000;122:3522-3
   PubMed Web of Science ®Google Scholar
• Hong L, Koelsch G, Lin X, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000;290:150-3
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Bilcer G, Harwood C, et al. Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 2001;44:2865-8
   PubMed Web of Science ®Google Scholar
• Tang J, Hong L, Ghosh AK. Inhibitors of memapsin 2 and use thereof. PCT Int Appl. WO2001000665; 2001
   Google Scholar
• Ghosh AK, Devasamudram T, Hong L, et al. Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). Bioorg Med Chem Lett 2005;15:15-20
   PubMed Web of Science ®Google Scholar
• Shuto D, Kasai S, Kimura T, et al. KMI-008, a Novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides. Bioorg Med Chem Lett 2003;13:4273-6
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Matsui J, Fukumoto H, Tarui N. Preparation of 2-[2-amino- or 2-(N-heterocyclyl)ethyl]-6-(4-biphenylylmethoxy)tetralin derivatives as beta-secretase inhibitors. PCT Int Appl. WO2001087293A1; 2001
   Google Scholar
• Watanabe H, Kurasawa O, Tarui N, et al. Preparation of indoles as inhibitors against aspartate protease, beta-secretase, and amyloid beta protein for treatment of nerve disorders and myopathy. Jpn Pat Appl. JP2004149429A; 2004
   Google Scholar
• Fukumoto H, Takahashi H, Tarui N, et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates A beta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 2010;30(33):11157-66
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Kumaragurubaran N, Hong L, et al. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem 2007;50(10):2399-407
   PubMed Web of Science ®Google Scholar
• Fang LY, Hom R, John V, Maillaird M. Preparation of substituted amines for treating Alzheimer's disease. PCT Int Appl. WO2002002505A2; 2002
   Google Scholar
• Maillaird M, Hom C, Gailunas A, et al. Preparation of substituted amines to treat Alzheimer's disease. PCT Int Appl. WO2002002512A2; 2002
   Google Scholar
• Beck JP, Gailunas A, Hom R, et al. Preparation of disubstituted amines for treating Alzheimer's disease. PCT Int Appl. WO2002002520A2; 2002
   Google Scholar
• Schostarez HJ, Chrusciel RA, Centko RS. Acylaminopropylhydrazines as beta-secretase inhibitors. PCT Int Appl. WO2002094768A2; 2002
   Google Scholar
• Schostarez HJ, Chrusciel RA. Preparation of peptide-related hydrazine derivatives for treating Alzheimer's disease. PCT Int Appl. WO2002100410A1; 2002
   Google Scholar
• Schostarez HJ, Chrusciel RA. Preparation of aminediols as beta-secretase inhibitors for the treatment of Alzheimer's and other diseases characterized by deposition of Abeta peptide. PCT Int Appl. WO2002100818A2; 2002
   Google Scholar
• Maillard M, Tucker JA. Substituted aminoalcohols useful in treatment of Alzheimer's disease. PCT Int Appl. WO2002100820A1; 2002
   Google Scholar
• John V, Hom R, Tucker J. Preparation of beta-hydroxyamine derivatives for the treatment of Alzheimer's disease. PCT Int Appl. WO2003002122A1; 2003
   Google Scholar
• Schostarez HJ, Chrusciel RA. Preparation of diamine diols as beta-secretase inhibitors for the treatment of Alzheimer's disease. PCT Int Appl. WO2003006013A1; 2003
   Google Scholar
• Schostarez HJ, Chrusciel RA. Preparation of statine derivatives for the treatment of Alzheimer's disease. PCT Int Appl. WO2003006021A1; 2003
   Google Scholar
• Gailunas A, Hom R, John V, et al. Preparation of N-(3-amino-2-hydroxy-propyl) substituted alkanamides as inhibitors of the beta secretase enzyme for treating Alzheimer's disease. PCT Int Appl. WO2003006423A1; 2003
   Google Scholar
• Schostarez HJ, Chrusciel RA. Preparation of amine diols as beta-secretase inhibitors for the treatment of Alzheimer's disease. PCT Int Appl. WO2003006453A1; 2003
   Google Scholar
• Hom RK, Fang LY, Mamo S, et al. Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. J Med Chem 2003;46:1799-802
   PubMed Web of Science ®Google Scholar
• Varghese J, Maillard M, Jagodzinska B, et al. Preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease. PCT Int Appl. WO2003040096A2; 2003
   Google Scholar
• Romero AG, Schostarez H, Roels CM. Preparation of amine 1,2- and 1,3-diol alditols and their use for treatment of Alzheimer's disease. PCT Int Appl. WO2003043975A1; 2003
   Google Scholar
• Hu J, Cwi CL, Smiley DL, et al. Design and synthesis of statine-containing BACE inhibitors. Bioorg Med Chem Lett 2003;4335-9
   PubMed Web of Science ®Google Scholar
• Lamar J, Hu J, Bueno AB, et al. Phe*-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR. Bioorg Med Chem Lett 2004;14(1):239-43
   PubMed Web of Science ®Google Scholar
• Chen SH, Lamar J, Guo D, et al. P3 cap modified Phe*-Ala series BACE inhibitors. Bioorg Med Chem Lett 2004;14(1):245-50
   PubMed Web of Science ®Google Scholar
• Kimura T, Shuto D, Kasai S, et al. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine. Bioorg Med Chem Lett 2004;14:1527-31
   PubMed Web of Science ®Google Scholar
• Kimura T, Shuto D, Hamada Y, et al. Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg Med Chem Lett 2005;15:211-15
   PubMed Web of Science ®Google Scholar
• Asai M, Hattori C, Iwata N, et al. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006;96:533-40
   PubMed Web of Science ®Google Scholar
• Kimura T, Hamada Y, Stochaj M, et al. Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisostere. Bioorg Med Chem Lett 2006;16:2380-6
   PubMed Web of Science ®Google Scholar
• Hamada Y, Igawa N, Ikari H, et al. Beta-Secretase inhibitors: modification at the P4 position and improvement of inhibitory activity in cultured cells. Bioorg Med Chem Lett 2006;16:4354-9
   PubMed Web of Science ®Google Scholar
• Hamada Y, Abdel-Rahman H, Yamani A, et al. BACE1 inhibitors: optimization by replacing the P1' residue with non-acidic moiety. Bioorg Med Chem Lett 2008;18:1649-53
   PubMed Web of Science ®Google Scholar
• Hamada Y, Ohta H, Miyamoto N, et al. Significance of interaction of BACE1-Arg235 with its ligands and design of BACE1 inhibitors with P2 pyridine scaffold. Bioorg Med Chem Lett 2009;19:2435-9
   PubMed Web of Science ®Google Scholar
• Hamada Y, Ishiura S, Kiso Y. BACE1 inhibitor peptides: can an infinitely small kcat value turn the substrate of an enzyme into its inhibitor? ACS Med Chem Lett 2012;3:193-
   PubMed Web of Science ®Google Scholar
• Hamada Y, Tagad HD, Nishimura Y, et al. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design. Bioorg Med Chem Lett 2012;22:1130-5
   PubMed Web of Science ®Google Scholar
• Maillard MC, Hom RK, Benson TE, et al. Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. J Med Chem 2007;50:776-81
   PubMed Web of Science ®Google Scholar
• Kortum SW, Benson TE, Bienkowski MJ, et al. Potent and selective isophthalamide S2 hydroxyethylamine inhibitors of BACE1. Bioorg Med Chem Lett 2007;17:3378-83
   PubMed Web of Science ®Google Scholar
• Freskos JN, Fobian YM, Benson TE, et al. Design of potent inhibitors of human beta-secretase. Part 1. Bioorg Med Chem Lett 2007;17:73-7
   PubMed Web of Science ®Google Scholar
• Freskos JN, Fobian YM, Benson TE, et al. Design of potent inhibitors of human beta-secretase. Part 2. Bioorg Med Chem Lett 2007;17:78-81
   PubMed Web of Science ®Google Scholar
• Brady SF, Singh S, Crouthamel MC, et al. Rational design and synthesis of selective BACE-1 inhibitors. Bioorg Med Chem Lett 2004;14:601-4
   PubMed Web of Science ®Google Scholar
• Coburn CA, Stachel SJ, Li YM. Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J Med Chem 2004;47:6117-19
   PubMed Web of Science ®Google Scholar
• Stachel SJ, Coburn CA, Steele TG, et al. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem 2004;47:6447-50
   PubMed Web of Science ®Google Scholar
• Stachel SJ, Coburn CA, Steele TG, et al. Conformationally biased P3 amide replacements of beta-secretase inhibitors. Bioorg Med Chem Lett 2006;16:641-4
   PubMed Web of Science ®Google Scholar
• Coburn CA, Stachel SJ, Jones KG, et al. BACE-1 inhibition by a series of psi[CH2NH] reduced amide isosteres. Bioorg Med Chem Lett 2006;16:3635-8
   PubMed Web of Science ®Google Scholar
• Rajapakse HA, Nantermet PG, Selnick HG, et al. Discovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1). J Med Chem 2006;49:7270-3
   PubMed Web of Science ®Google Scholar
• McGaughey GB, Colussi D, Graham SL, et al. Beta-secretase (BACE-1) inhibitors: accounting for 10s loop flexibility using rigid active sites. Bioorg Med Chem Lett 2007;17:1117-21
   PubMed Web of Science ®Google Scholar
• Stauffer SR, Stanton MG, Gregro AR, et al. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind beta-secretase in a N-terminal 10s-loop down conformation. Bioorg Med Chem Lett 2007;17:1788-92
   PubMed Web of Science ®Google Scholar
• Lindsley SR, Moore KP, Rajapakse HA, et al. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 2007;17:4057-61
   PubMed Web of Science ®Google Scholar
• Moore KP, Zhu H, Rajapakse HA, et al. Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 2007;17:5831-5
   PubMed Web of Science ®Google Scholar
• Zhu H, Young MB, Nantermet PG, et al. Rapid P1 SAR of brain pemetral tertial carbinamine derived BACE inhibitor. Bioorg Med Chem Lett 2010;20(5):1779-82
   PubMedGoogle Scholar
• Hamada Y, Ohta H, Miyamoto N, et al. Novel non-peptidic and small-sized BACE1 inhibitors. Bioorg Med Chem Lett 2008;18:1654-8
   Web of Science ®Google Scholar
• Hamada Y, Nakanishi T, Suzuki K, et al. Novel BACE1 inhibitors possessing a 5-nitroisophthalic scaffold at the P2 position. Bioorg Med Chem Lett 2012;22:4640-4
   PubMed Web of Science ®Google Scholar
• Demont EH, Faller A, MacPherson DT, et al. Preparation of hydroxyethylamine derivatives for the treatment of Alzheimer's disease. PCT Int Appl. WO2004050619A1; 2004
   Google Scholar
• Demont EH, Redshaw S, Walter DS. Preparation of hydroxyethylamine derivatives for the treatment of Alzheimer's disease. PCT Int Appl. WO2004080376A2; 2004
   Google Scholar
• Demont EH, Redshaw S, Walter DS. Preparation of hydroxydiaminopropyl tricyclic indolecarboxamides for treatment of beta-amyloid related disease. PCT Int Appl. WO2004094430A1; 2004
   Google Scholar
• Demont EH, Redshaw S, Walter DS. Preparation of 3-(1,1-dioxotetrahydro-1, 2-thiazin-2-yl) or 3-(1,1-dioxo-isothiazolidin-2-yl) substituted benzamide compounds for treatment of Alzheimer's disease. PCT Int Appl. WO2004111022A1; 2004
   Google Scholar
• Redshaw S, Demont EH, Walter DS. Preparation of tricyclic indole hydroxyethylamine derivatives and their use in the treatment of Alzheimer's disease. PCT Int Appl. WO2005058915A1; 2005
   Google Scholar
• Demont EH, Redshaw S, Walter DS. Preparation of N,N'-substituted-1,3-diamino-2-oxopropane derivatives as Asp2 inhibitors for use against diseases characterized by elevated beta-amyloid levels or beta-amyloid deposits, particularly Alzheimer's disease. PCT Int Appl. WO2005113525A1; 2005
   Google Scholar
• Demont EH, Redshaw S, Walter DS. Heterocyclic ketone compounds for treating Alzheimer's disease. PCT Int Appl. WO2006040149A1; 2006
   Google Scholar
• Demont EH, Redshaw S, Walter DS. Preparation of substituted hydroxyethylamine compounds for treating Alzheimer's disease. PCT Int Appl. WO2006040151A1; 2006
   Google Scholar
• Demont EH, Redshaw S, Walter DS. Tricyclic indole derivatives for use in the treatment of Alzheimer's disease. PCT Int Appl. WO2006040148A1; 2006
   Google Scholar
• Clarke B, Demont E, Dingwall C, et al. BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs). Bioorg Med Chem Lett 2008;18:1011-16
   PubMed Web of Science ®Google Scholar
• Clarke B, Demont E, Dingwall C, et al. BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character. Bioorg Med Chem Lett 2008;18:1017-21
   PubMed Web of Science ®Google Scholar
• Beswick P, Charrier N, Clarke B, et al. BACE-1 inhibitors part 3: identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells. Bioorg Med Chem Lett 2008;18:1022-6
   PubMed Web of Science ®Google Scholar
• Iserloh U, Wu Y, Cumming JN, et al. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors. Bioorg Med Chem Lett 2008;18(1):414-17
   PubMed Web of Science ®Google Scholar
• Iserloh U, Pan J, Stamford AW, et al. Discovery of an orally efficacious 4-phenoxypyrrolidine-based BACE-1 inhibitor. Bioorg Med Chem Lett 2008;18(1):418-22
   PubMed Web of Science ®Google Scholar
• Cumming JN, Le TX, Babu S. Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors. Bioorg Med Chem Lett 2008;18(11):3236-41
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Kumaragurubaran N, Hong L, et al. Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett 2008;18(3):1031-6
   PubMed Web of Science ®Google Scholar
• Chang WP, Huang X, Downs D, et al. Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J 2011;25(2):775-84
   PubMed Web of Science ®Google Scholar
• Decicco CP, Tebben AJ, Thompson LA, Combs AP. Preparation of novel alpha-amino-gamma-lactams as beta-secretase inhibitors. PCT Int Appl. WO2004013098A1; 2004
   Google Scholar
• Rueeger H, Rondeau JM, McCarthy C, et al. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors. Bioorg Med Chem Lett 2011;21(7):1942-7
   PubMed Web of Science ®Google Scholar
• Rueeger H, Lueoend R, Rogel O, et al. Discovery of cyclic sulfone hydroxyethylamines as potent and selective beta-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid beta-peptides. J Med Chem 2012;55(7):3364-86
   PubMed Web of Science ®Google Scholar
• Monenscheinc H, Hornea DB, Bartbergerb MD, et al. Structure guided P1' modifications of HEA derived beta-secretase inhibitors for the treatment of Alzheimer's disease. Bioorg Med Chem Lett 2012;22(11):3607-11
   PubMed Web of Science ®Google Scholar
• Weiss MW, Williamson T, Babu-Khan S, et al. Design and preparation of a potent series of hydroxyethylamine containing beta-secretase inhibitors that demonstrate robust reduction of central beta-amyloid. J Med Chem 2012;55(21):9009-24
   PubMed Web of Science ®Google Scholar
• Dineen TA, Weiss MM, Williamson T, et al. Beta-Site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem 2012;55(21):9025-44
   PubMed Web of Science ®Google Scholar
• Cole DC, Manas ES, Stock JR, et al. Acylguanidines as small-molecule beta-secretase inhibitors. J Med Chem 2006;49:6158-61
   PubMed Web of Science ®Google Scholar
• Fobare WF, Solvibile WR, Robichaud AJ, et al. Thiophene substituted acylguanidines as BACE1 inhibitors. Bioorg Med Chem Lett 2007;17:5353-6
   PubMed Web of Science ®Google Scholar
• Jennings LD, Cole DC, Stock JR, et al. Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S′1 substrate binding pocket. Bioorg Med Chem Lett 2008;18:767-71
   PubMed Web of Science ®Google Scholar
• Cole DC, Stock JR, Chopra R, et al. Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. Bioorg Med Chem Lett 2008;18:1063-6
   PubMed Web of Science ®Google Scholar
• Hu B. Preparation of terphenylguanidines as beta-secretase inhibitors for inhibition of the formation of beta-amyloid deposits and neurofibrillary tangles present in neurodegenerative diseases. US Pat Appl. US2006183943A1; 2006
   Google Scholar
• Cole DC, Manas ES, Jennings LD, et al. Preparation of azolylacylguanidines as beta-secretase inhibitors. US Pat Appl. US2006183790A1; 2006
   Google Scholar
• Fobare WF, Solvibile WR. Preparation of thienyl and furyl acylguanidines as beta-secretase (BACE) inhibitors. US Pat Appl. US2006183792A1; 2006
   Google Scholar
• Malamas MS, Erdei JJ, Gunawan IS, et al. Preparation of amino-5,5-diphenylimidazolone derivatives for inhibition of beta-secretase and treatment of beta-amyloid-related diseases. US Pat Appl. US2005282825A1; 2005
   Google Scholar
• Malamas MS, Erdei JJ, Gunawan IS, et al. Preparation of diphenylimidazopyrimidine and -imidazole amines as selective inhibitors of beta-secretase for use against Alzheimer's disease and other disorders. US Pat Appl. US2005282826A1; 2005
   Google Scholar
• Malamas MS, Erdei JJ, Gunawan IS, et al. Preparation of 8,8-diphenyl-2,3,4, 8-tetrahydroimidazo[1,5-a]pyrimidin-6-amines as beta-secretase inhibitors for the treatment of Alzheimer's disease and related disorders. PCT Int Appl. WO2006076284A2; 2006
   Google Scholar
• Malamas MS, Fobare WF, Solvibile WR, et al. Amino-pyridines as inhibitors of beta-secretase and their preparation, and pharmaceutical compositions. US Pat Appl. US2006173049A1; 2006
   Google Scholar
• Zhou PM, Michael S, Li Y, et al. Preparation of aminoheteroarylimidazolone compounds for use as beta-secretase modulators to treat beta-amyloid and neurofibrillary tangle associated diseases. US Pat Appl. US2007004730A1; 2007
   Google Scholar
• Malamas MS, Zhou P, Fobare WF, et al. Preparation of amino-5-(5-membered)hetero-arylimidazolone compounds as beta-secretase modulators for treating diseases involving beta-amyloid deposits and neurofibrillary tangles. US Pat Appl. US2007004786A1; 2007
   Google Scholar
• Malamas MS, Gunawan IS, Erdei JJ, et al. Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation and treatment of diseases with beta-amyloid deposits and neurofibrillary tangles. US Pat Appl. US2007027199A1; 2007
   Google Scholar
• Malamas MS, Erdei JJ, Fobare WF, et al. Preparation of imidazolone derivatives as inhibitors of beta-secretase. US Pat Appl. US2007072925A1; 2007
   Google Scholar
• Zhou P, Bernotas RC, Li Y, et al. Preparation of 2-amino-5-phenyl-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation. PCT Int Appl. WO2007078813A2; 2007
   Google Scholar
• Quagliato DA, Andrae PM, Fan Y. Preparation of spirodibenzoannulene-imidazolones as inhibitors of beta-secretase (BACE). US Pat Appl. US2007203116A1; 2007
   Google Scholar
• Malamas MS, Barnes KD, Johnson MR. Imidazole amines as inhibitors of beta-secretase and their preparation, pharmaceutical compositions and use in the treatment of diseases associated with elevated beta-amyloid deposits and beta-amyloid levels. PCT Int Appl. WO2008022024A2; 2008
   Google Scholar
• Malamas MS, Robichaud AJ, Porte AM, et al. Amino-5-[substituted-4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as beta-secretase inhibitors and their preparation, and use in the treatment of beta-amyloid deposits and neurofibrillary tangles. PCT Int Appl. WO2008115552A1; 2008
   Google Scholar
• Malamas MS, Robichaud AJ, Porte AM, et al. Preparation of amino-5- [4-(difluoromethoxy)phenyl]-5-phenylimidazolone derivatives as inhibitors of beta-secretase. PCT Int Appl. WO2008118379A2; 2008
   Google Scholar
• Malamas MS, Erdei J, Gunawan I, et al. Design and synthesis of potent, orally efficacious hydroxyethylamine derived design and synthesis of 5,5′-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. J Med Chem 2010;53(3):1146-58
   PubMed Web of Science ®Google Scholar
• Malamas MS, Barnes K, Johnson M, et al. Di-substituted pyridinyl aminohydantoins as potent and highly selective human beta-secretase (BACE1) inhibitors. Bioorg Med Chem 2010;18(2):630-9
   PubMed Web of Science ®Google Scholar
• Nowak P, Cole DC, Aulabaugh A, et al. Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett 2010;20(2):632-5
   PubMed Web of Science ®Google Scholar
• Zhou P, Li Y, Fan Y, et al. Pyridinyl aminohydantoins as small molecule BACE1 inhibitors. Bioorg Med Chem Lett 2010;20(7):2326-9
   PubMed Web of Science ®Google Scholar
• Malamasa MS, Robichauda A, Erdeia J, et al. Design and synthesis of aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors with enhanced brain permeability. Bioorg Med Chem Lett 2010;20(22):6597-605
   PubMed Web of Science ®Google Scholar
• Barrow JC, Stauffer SR, Rittle KE, et al. Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase. J Med Chem 2008;51(20):6259-62
   PubMed Web of Science ®Google Scholar
• Stachel SJ, Coburn CA, Rush D, et al. Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1. Bioorg Med Chem Lett 2009;19(11):2977-80
   PubMed Web of Science ®Google Scholar
• Hills ID, Holloway MK, de León P, et al. A conformational constraint improves a beta-secretase inhibitor but for an unexpected reason. Bioorg Med Chem Lett 2009;10(17):4993-5
   Google Scholar
• Steelea TG, Hillsa ID, Nomlanda AA, et al. Identification of a small molecule beta-secretase inhibitor that binds without catalytic aspartate engagement. Bioorg Med Chem Lett 2009;19(1):17-20
   PubMed Web of Science ®Google Scholar
• Baxter EW, Conway KA, Kennis L, et al. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem 2007;50:4261-4
   PubMed Web of Science ®Google Scholar
• Huanga Y, Strobela ED, Hoa CY, et al. Macrocyclic BACE inhibitors: optimization of a micromolar hit to nanomolar leads. Bioorg Med Chem Lett 2010;20(10):3158-60
   PubMed Web of Science ®Google Scholar
• Geschwindner S, Olsson LL, Albert JS, et al. Discovery of a novel warhead against beta-secretase through fragment-based lead generation. J Med Chem 2007;50:5903-11
   PubMed Web of Science ®Google Scholar
• Edwards PD, Albert JS, Sylvester M, et al. Appl.ication of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J Med Chem 2007;50:5912-25
   PubMed Web of Science ®Google Scholar
• Murray XW, Callagham O, Chessari G, et al. Appl.ication of fragment screening by X-ray crystallography to beta-secretase. J Med Chem 2007;50:1116-23
   PubMed Web of Science ®Google Scholar
• Congreve M, Aharony D, Albert J, et al. Appl.ication of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. J Med Chem 2007;50:1124-32
   PubMed Web of Science ®Google Scholar
• Chiriano G, Sartini A, Mancini F, et al. Sequential virtual screening approach to the identification of small organic molecules as potential BACE-1 inhibitors. Chem Biol Drug Des 2011;77(4):268-71
   PubMed Web of Science ®Google Scholar
• Yang W, Fucini RV, Fahr BT, et al. Fragment-based discovery of nonpeptidic BACE-1 inhibitors using Tethering. Biochemistry 2009;48(21):4488-96
   PubMed Web of Science ®Google Scholar
• Wang YS, Strickland C, Voigt JH, et al. Appl.ication of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel mu M leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. J Med Chem 2010;53(3):942-50
   PubMed Web of Science ®Google Scholar
• Zhu Z, Sun Z-Y, Ye Y, et al. Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I. Inhibitor design and validation. J Med Chem 2010;53(3):951-65
   PubMed Web of Science ®Google Scholar
• Madden J, Dod JR, Godemann R, et al. Fragment-based discovery and optimization of BACE1 inhibitors. Bioorg Med Chem Lett 2010;20(17):5329-33
   PubMed Web of Science ®Google Scholar
• Efremov IV, Vajdos FF, Borzilleri KA, et al. Discovery and optimization of a novel spiropyrrolidine inhibitor of beta-secretase (BACE1) through fragment-based drug design. J Med Chem 2012;55(21):9069-88
   PubMed Web of Science ®Google Scholar
• Cheng Y, Judd TC, Bartberger MD, et al. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). J Med Chem 2011;54(16):5836-57
   PubMed Web of Science ®Google Scholar
• May PC, Dean RA, Lowe SL, et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci 2011;31(46):16507-16
   PubMed Web of Science ®Google Scholar
• Jeppsson F, Eketjäll S, Janson J, et al. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem 2012;287(49):41245-57
   PubMed Web of Science ®Google Scholar
• Cosconati S, Marinelli L, Di Leva FS, et al. Protein flexibility in virtual screening: the BACE-1 case study. J Chem Inf Model 2012;52(10):2697-704
   PubMed Web of Science ®Google Scholar
• Huang D, Luethi U, Kolb P, et al. Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations. J Med Chem 2005;48:5108-11
   PubMed Web of Science ®Google Scholar
• Huang D, Luethi U, Kolb P, et al. In silico discovery of beta-secretase inhibitors. J Am Chem Soc 2006;128(16):5436-43
   PubMed Web of Science ®Google Scholar
• Kolb P, Caflisch A. Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking. J Med Chem 2006;49:7384-92
   PubMed Web of Science ®Google Scholar
• Williams P, Sorribas A, Howes M-J R, et al. Natural products as a source of Alzheimer's drug leads. Nat Prod Rep 2011;28:48-48-77
   PubMed Web of Science ®Google Scholar
• Viayna E, Gómes T, Galdeano C, et al. Novel huprine derivatives with inhibitory activity toward beta-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates. ChemMedChem 2010;5(11):1855-70
   PubMed Web of Science ®Google Scholar
• Camps P, Formosa X, Galdeano C, et al. Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem 2009;52(17):5365-79
   PubMed Web of Science ®Google Scholar